The DOI matches its Crossref record, with a small difference in title or year; 2 of the 2 references it cites were found in a registry or an index.
Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries
Abstract
Background & aims: Idiosyncratic drug‐induced liver injury (DILI) with autoimmune features is a liver condition with laboratory and histological characteristics similar to those of idiopathic autoimmune hepatitis (AIH), which despite being increasingly reported, remains largely undefined. We aimed to describe in‐depth the features of this entity in a large series of patients from two prospective DILI registries. Methods: DILI cases with autoimmune features collected in the Spanish DILI Registry and the Latin American DILI Network were compared with DILI patients without autoimmune features and with an independent cohort of patients with AIH. Results: Out of 1,426 patients with DILI, 33 cases with autoimmune features were identified. Female sex was more frequent in AIH patients than in the other groups (p = .001). DILI cases with autoimmune features had significantly longer time to onset (p < .001) and resolution time (p = .004) than those without autoimmune features. Interestingly, DILI patients with autoimmune features who relapsed exhibited significantly higher total bilirubin and transaminases at onset and absence of peripheral eosinophilia than those who did not relapse. The likelihood of relapse increased over time, from 17% at 6 months to 50% 4 years after biochemical normalization. Statins, nitrofurantoin and minocycline were the drugs most frequently associated with this phenotype. Conclusions: DILI with autoimmune features shows different clinical features than DILI patients lacking characteristics of autoimmunity. Higher transaminases and total bilirubin values with no eosinophilia at presentation increase the likelihood of relapse in DILI with autoimmune features. As the tendency to relapse increases over time, these patients will require long‐term follow‐up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment decisions are often based on experience gained from case reports or expert opinion.
“Treatment decisions are often based on experience gained from case reports or expert opinion.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [51]
DI-ALH presents as a self-limited phenotype that resolves or becomes quiescent when the drug is removed, but in some cases liver injury progresses to chronicity and a self-perpetuating autoimmune liver disease ensues.
“Thus, DI-AHL presents as a “self-limited” phenotype that resolves or becomes quiescent when the drug is removed, but in some cases, liver injury does progress to chronicity and a “self-perpetuating” autoimmune liver disease ensues (Fig. 2).22,51,52”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [51]
In a long-term follow-up of DI-ALH cases collected in two prospective DILI registries, the likelihood of relapse increased over time, reaching 50% after more than 4 years of follow-up.
“Interestingly, however, in a long-term follow-up of DI-ALH cases collected in two prospective DILI registries, the likelihood of relapse increased over time, reaching 50% after more than 4 years of follow-up.51”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [51]
In the recent analysis of DI-ALH in the Spanish and the Latin-American registries, the probability of a relapse in patients grouped as having DI-ALH increased with time, being 17% at 6 months and 50% after 4 years of follow-up after remission.
“Interestingly, in the recent analysis of DI-ALH in the Spanish and the Latin-American registries, the probability of a relapse in patients grouped as having DI-ALH increased with time, being 17% at 6 months and 50% after 4 years of follow-up after remission.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citation
Flagged first, then by citations
Research works printed but not linked: 30
- 10.1002/hep.31065 · DOI · Paper page
- 10.1016/j.jaut.2021.102706 · DOI
- 10.1111/j.1749-6632.1965.tb19000.x · DOI
- 10.1002/hep.23584 · DOI · Paper page
- 10.1002/hep.23588 · DOI · Paper page
- 10.1016/j.cgh.2016.05.043 · DOI · Paper page
- 10.1016/j.jhep.2010.12.041 · DOI · Paper page
- 10.4254/wjh.v6.i4.160 · DOI · Paper page
- 10.1136/gutjnl-2016-313369 · DOI · Paper page
- 10.1111/liv.15378 · DOI · Paper page
- 10.1016/j.jhep.2021.01.029 · DOI · Paper page
- 10.3390/ijms17030313 · DOI
- 10.1016/0168-8278(90)90124-A · DOI · Paper page
- 10.1038/clpt.2011.58 · DOI · Paper page
- 10.1016/S0168-8278(99)80297-9 · DOI · Paper page
- 10.1007/s00535-015-1131-7 · DOI
- 10.1002/hep4.1959 · DOI · Paper page
- 10.1111/hepr.12532 · DOI
- 10.1016/j.jhep.2022.09.010 · DOI
- 10.1007/s00204-022-03419-7 · DOI
- 10.1002/hep4.1582 · DOI · Paper page
- 10.1002/hep.32134 · DOI · Paper page
- 10.1111/hepr.13532 · DOI
- 10.1016/j.cgh.2017.05.027 · DOI · Paper page
- 10.1111/j.1468-3083.2006.01838.x · DOI
- 10.1111/j.1365-2036.2007.03330.x · DOI
- 10.1016/j.jhep.2008.03.017 · DOI
- 10.1016/j.cgh.2012.12.025 · DOI · Paper page
- 10.1016/j.jhep.2008.10.021 · DOI · Paper page
- 10.1007/s10620-011-1611-4 · DOI · Paper page
Cited by
Sorted by citations
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citation
Metadata
- Authors
- García‐Cortés, M., Ortega‐Alonso, A., Matilla‐Cabello, G., Medina‐Cáliz, I., Castiella, A., Conde, I., Bonilla‐Toyos, E., Pinazo‐Bandera, J., Hernández, N., Tagle, M., Nunes, V., Parana, R., Bessone, F., Kaplowitz, N., Lucena, M. I., Alvarez‐Alvarez, I., Robles‐Díaz, M., & Andrade, R. J.
- Affiliations
- Servicios de Aparato Digestivo and Farmacología Clínica Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND, Universidad de Málaga Málaga Spain
- Servicio de Gastroenterología, Hospital Universitario de Donostia San Sebastián Spain
- Servicio de Aparato Digestivo Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe Valencia Spain
- Hospital de Clínicas Universidad de la República Montevideo Uruguay
- Universidad Peruana Cayetano Heredia Lima Peru
- Hospital Universitario Prof. Edgard Santos Salvador de Bahia Brazil
- Universidad Federal de Bahia Bahia Brazil
- Hospital Provincial del Centenario, Facultad de Medicina, Universidad Nacional de Rosario Rosario Argentina
- University of Southern California Research Center for Liver Diseases, Keck School of Medicine, University of Southern California Los Angeles California USA
- ORCID
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2023-06-03
- Volume
- 43
- Issue
- 8
- Pages
- 1749-1760
- ISSN
- 1478-3223
- 1478-3231
- Cited by
- 32
- References
- 2
- Language
- en
- Funders
- Instituto de Salud Carlos III
- European Cooperation in Science and Technology
- Universidad de Málaga
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review